Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Alan J. Korman"'
Autor:
Mark J. Smyth, Georgina V. Long, Ruth Y. Lan, Alan J. Korman, Richard A. Scolyer, Kazuyoshi Takeda, Stephen J. Blake, Kimberley Stannard, Ailin Lepletier, Jason Madore, William C. Dougall, Deepak Mittal, Vicki L. J. Whitehall, Amelia Roman Aguilera, Michele W.L. Teng, Cheng Liu, Robert J. Johnston, Nathan O. Siemers, Mark Bettington
Publikováno v:
Cancer Immunology Research. 7:559-571
CD96 is a novel target for cancer immunotherapy shown to regulate NK cell effector function and metastasis. Here, we demonstrated that blocking CD96 suppressed primary tumor growth in a number of experimental mouse tumor models in a CD8+ T cell–dep
Autor:
Rob Woestenenk, Vera E. Mekers, Jeannette Cany, Somayeh Rezaeifard, Alan J. Korman, Nicolaas Schaap, Paul K J D de Jonge, Joop H. Jansen, Harry Dolstra, Janneke S. Hoogstad-van Evert, Leon F.A.G. Massuger, Jolien M R van der Meer, Ralph J. A. Maas, Willemijn Hobo
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
Oncoimmunology, 9, 1
Oncoimmunology, 9
OncoImmunology, Vol 9, Iss 1 (2020)
article-version (VoR) Version of Record
Oncoimmunology, 9, 1
Oncoimmunology, 9
OncoImmunology, Vol 9, Iss 1 (2020)
Advanced ovarian cancer (OC) patients have a poor 5-year survival of only 28%, emphasizing the medical need for improved therapies. Adjuvant immunotherapy could be an attractive approach since OC is an immunogenic disease and the presence of tumor-in
Autor:
Karen Forbes, Xiaoyu Pan, Charles G. Drake, Andrea L. Szymczak-Workman, Alan J. Korman, Maria Bettini, Ashley H. Castellaw, Dario A. A. Vignali, Mark J. Selby
Publikováno v:
The Journal of Immunology. 187:3493-3498
Lymphocyte activation gene-3 (LAG-3; CD223) is a CD4 homolog that is required for maximal regulatory T cell function and for the control of CD4+ and CD8+ T cell homeostasis. Lag3−/− NOD mice developed substantially accelerated diabetes with 100%
Autor:
Alan J. Korman, Robbert van der Voort, Theo de Witte, J.H. Frederik Falkenburg, Michel G.D. Kester, Frans Maas, Harry Dolstra, Nicolaas Schaap, Wieger J. Norde, Michael Quigley, Willemijn Hobo, Konnie M. Hebeda
Publikováno v:
Cancer Research, 71(15), 5111-5122
Cancer Research, 71, 5111-22
Cancer Research, 71, 15, pp. 5111-22
Cancer Research, 71, 5111-22
Cancer Research, 71, 15, pp. 5111-22
Contains fulltext : 97194.pdf (Publisher’s version ) (Closed access) Tumor relapses remain a serious problem after allogeneic stem cell transplantation (alloSCT), despite the long-term persistence of minor histocompatibility antigen (MiHA)-specific
Autor:
David Berman, R. Humphrey, Ramy Ibrahim, Alan J. Korman, Renzo Canetta, Axel Hoos, Kevin M. Chin, Vafa Shahabi, Kald Abdallah
Publikováno v:
Seminars in Oncology. 37:533-546
Identification of cytotoxic T-lymphocyte antigen-4 (CTLA-4) as a key negative regulator of T-cell activity led to development of the fully human, monoclonal antibody ipilimumab to block CTLA-4 and potentiate antitumor T-cell responses. Animal studies
Autor:
Sara M. Mangsbo, Linda C. Sandin, Thomas H. Tötterman, Alan J. Korman, Angelica Loskog, Kerstin Anger
Publikováno v:
Journal of Immunotherapy. 33:225-235
Tumor immunotherapy aims to break effector T-cell anergy and to block suppressive cell types and ligands allowing effector cells to exert tumor eradication. Previous reports demonstrate that cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antibodi
Publikováno v:
The Journal of Experimental Medicine
Cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) is a critical negative regulator of immune responses. Uniquely among known inhibitory receptors, its genetic ablation results in a fulminating and fatal lymphoproliferative disorder. This central
Autor:
Michael T. Jaklitsch, Frank G. Haluska, Marybeth Nelson, Sara Russell, James P. Allison, Darryl A. Oble, Alan J. Korman, Glenn Dranoff, Nikhil H. Ramaiya, F. Stephen Hodi, Suzanne MacRae, Christine Canning, Israel Lowy, Donna Neuberg, Teresa C. Chen, David B. Lautz, Martin C. Mihm, Marcus O. Butler, Michael V. Seiden, Andrea Kruse
Publikováno v:
Proceedings of the National Academy of Sciences. 105:3005-3010
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) functions as a negative regulator of endogenous and vaccine-induced antitumor immunity. The administration of fully human anti-CTLA-4 blocking monoclonal antibodies to advanced-cancer patients incr
Autor:
Raymond M. Wong, W.M. Kast, Jeffrey S. Weber, Roy L. Lau, Alan J. Korman, Ron R. Scotland, Changyu Wang
Publikováno v:
International Immunology. 19:1223-1234
Negative co-stimulatory signaling mediated via cell surface programmed death (PD)-1 expression modulates T and B cell activation and is involved in maintaining peripheral tolerance. In this study, we examined the effects of a fully human PD-1-abrogat
Publikováno v:
Current Opinion in Immunology. 18:206-213
Cytotoxic T lymphocyte antigen-4 has become recognized as one of the key negative regulators of adaptive immune responses, having a central role in the maintenance of peripheral tolerance and in shaping the repertoire of emergent T cell responses. Co